Concepedia

Joerg Schlingemann

JS

7

Publications

409

Citations

7

H-Index

2021

Active since

Affiliations

Merck (Germany)(Current)

AstraZeneca (United Kingdom)

Merck & Co., Inc., Rahway, NJ, USA (United States)

United States Pharmacopeial Convention

Joerg Schlingemann is an author at Merck (Germany) specializing in drug discovery, drug development, and drug analysis.

Top concepts

MedicinePharmacologyDrug AnalysisDrug DiscoveryDrug DevelopmentMedicinal ChemistryToxicologyBiochemistryNatural SciencesBioanalysis

Publications per year

2021–2023

7

Publications

7

The Landscape of Potential Small and Drug Substance Related Nitrosamines in Pharmaceuticals

Joerg Schlingemann, Michael J. Burns, David J. Ponting et al. · Journal of Pharmaceutical Sciences · 2022 · 115 citations · Full text

A Nitrite Excipient Database: A Useful Tool to Support N-Nitrosamine Risk Assessments for Drug Products

Ruth Boetzel, Joerg Schlingemann, Sebastian Hickert et al. · Journal of Pharmaceutical Sciences · 2022 · 83 citations

Drug Safety, Medicinal Chemistry, Predictive Toxicology +13

The Nitrosamine “Saga”: Lessons Learned from Five Years of Scrutiny

Raphael Nudelman, Grace Kocks, Bruno Mouton et al. · Organic Process Research & Development · 2023 · 68 citations · Full text

Pharmaceutical Science, Na Exposure, Nitrosative Stress +17

Avoiding N-nitrosodimethylamine formation in metformin pharmaceuticals by limiting dimethylamine and nitrite

Joerg Schlingemann, Céline Boucley, Sebastian Hickert et al. · International Journal of Pharmaceutics · 2022 · 60 citations · Full text

Pharmaceutical Science, Methanol, Organic Chemistry +20

NDMA analytics in metformin products: Comparison of methods and pitfalls

Matthias Fritzsche, Giorgio Blom, Judith Keitel et al. · European Journal of Pharmaceutical Sciences · 2021 · 41 citations · Full text

Rows per page

1–5 of 7